Reported or proposed issue Pregnancy, breastfeeding, children, liver disease, or cancer history Evidence source No direct human safety data Known or theoretical
In a 2001 study published in Endocrinology , Heffernan and colleagues reported that chronic AOD-9604 administration reduced body weight gain, decreased adipose tissue mass, and increased fat oxidation in obese mice without altering IGF-1 levels or glucose metabolism effects that were abolished in beta3 adrenergic receptor (3-AR) knockout mice, implicating 3-AR signaling as the mechanism of action [1]
While peptide therapies are increasingly accessible, they are not without risks
Because the body is efficient at excreting excess B12 through urine, there is no established tolerable upper intake level (UL) for the vitamin
While Semaglutide and Tirzepatide have become household names, a growing number of patients are also exploring metabolic peptides such as AOD-9604, MOTS-c, and Tesamorelin
5-Amino-1MQ reduces NNMT, improving NAD+ retention, metabolism, and fat reduction in models.[4][5] Mouse studies demonstrate obesity reversal and muscle enhancement
)
